gullapalli

The initiative will also engage current joint programmes such as Lilly Scholars at Purdue and the Lilly and Purdue Research Alliance Center. Credit: Tada Images / Shutterstock. Eli Lilly and Purdue University, US, have announced the widening of their existing […]

BioVaxys’ technology incorporates bioactive molecules to generate long-lasting immune responses. Credit: Gorodenkoff/Shutterstock. BioVaxys Technology and Sona Nanotech have signed a research agreement to develop cancer therapeutics utilising the former’s DPX immune educating platform (DPX) along with Sona’s targeted hyperthermia therapy

Glioblastoma is an aggressive brain cancer form. Credit: Komsan Loonprom/Shutterstock. Contract development and manufacturing organisation (CDMO) Viralgen has partnered biotech company Trogenix to accelerate the development of a recombinant adeno-associated virus (rAAV) gene therapy for glioblastoma, an aggressive brain cancer.

Haya plans to use the funds to commence trials for HTX-001, initially aiming to target non-obstructive hypertrophic cardiomyopathy (nHCM). Credit: PanuShot / Shutterstock. Haya Therapeutics has procured $65m in Series A funding to expedite the clinical development of HTX-001 for

The cell lines are stated to be high-value solutions for the recombinant adeno-associated viruses (rAAV) manufacturing, for cell and gene therapy use. Credit: totojang1977 / Shutterstock. Swiss biotechnology company NewBiologix has given a non-exclusive technology licence to Recipharm Advanced Bio

In 2024, the medicines’ indications were expanded to include cardiovascular risk minimisation in individuals who are not to take recommended statin therapy. Credit: chayanuphol / Shutterstock. HLS Therapeutics has signed an agreement with Esperion Therapeutics for in-licensing and commercialising the

The partnership aims to optimise Regor’s platform to identify targets and treatments that meet the individuals’ requirements and preferences. Credit: aslysun/Shutterstock. Sermonix Pharmaceuticals and Regor Therapeutics have announced a strategic partnership to discover and develop therapeutics in the breast oncology

GSK’s mepolizumab programme in chronic obstructive pulmonary disease includes three studies. Credit: HJBC/Shutterstock. The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary disease (COPD)

The Arthur JE Child Comprehensive Cancer Centre. Credit: Alberta Health Services/Siemens Healthineers AG ©2025. The government of Alberta, Canada, has announced a collaboration with Siemens Healthineers and the Alberta Cancer Foundation, investing C$800m ($560m) over eight years to enhance cancer

The company’s mRNA therapies include TAA cancer vaccines, immunomodulatory cancer vaccines, in vivo CAR-T therapies and personalised cancer vaccines. Credit: Pormezz/Shutterstock. The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for Everest Medicines’ tumour-associated